Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17769122 | 0.98 | GRM2 (0.57) | GRM2NCOA1NCOA3ALDH1A1 | |
| Transtorine SCHEMBL22979 | 0.85 | ALOX15 (0.60) | ALDH1A1 | |
| Transtorine SCHEMBL17596601 | 0.85 | ALOX15 (0.60) | ALDH1A1 | |
| Transtorine SCHEMBL1421892 | 0.84 | ALOX15 (0.58) | ALDH1A1 | |
| Transtorine SCHEMBL480985 | 0.84 | ALOX15 (0.58) | ALDH1A1 | |
| SCHEMBL9667786 | 0.83 | GRM2 (0.43) | GRM2NCOA1NCOA3ALDH1A1 | |
| SCHEMBL9574610 | 0.82 | NCOA1 (0.60) | GRM2NCOA1NCOA3 | |
| SCHEMBL17718271 | 0.82 | ALDH1A1 (0.49) | GRM2ALDH1A1 | |
| SCHEMBL16832253 | 0.81 | KDM4E (0.58) | GRM2 | |
| SCHEMBL2708959 | 0.81 | GRM2 (0.63) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029159-A | Preparation scheme of benzimidazole compound | 拉夸里亚创药株式会社 | 2026-05-12 | — | — | CN | claimed |
| WO-2025095097-A1 | Process for producing benzimidazole compound | RAQUALIA PHARMA INC. (JP) | 2025-05-08 | — | — | WO | claimed |
| US-20090012118-A1 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-08 | — | — | US | claimed |
| CN-1989127-A | Kynurenic acid amide derivatives as NR2B receptor antagonists | RICHTER GEDEON VEGYESZET (HU) | 2007-06-27 | — | — | CN | claimed |
| EP-1771436-A1 | KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Richter Gedeon Vegy Szeti Gy R Rt. (HU) | 2007-04-11 | — | — | EP | claimed |
| WO-2006010967-A1 | KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | claimed |
| CN-122029159-A | Preparation scheme of benzimidazole compound | 拉夸里亚创药株式会社 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025095097-A1 | Process for producing benzimidazole compound | RAQUALIA PHARMA INC. (JP) | 2025-05-08 | — | — | WO | disclosed |
| CN-114624343-B | Method for relatively quantifying 45 inflammations and immune metabolites in serum | 中国科学院大连化学物理研究所 | 2023-01-24 | — | — | CN | disclosed |
| CN-114624343-A | Method for relative quantification of 45 inflammations and immune metabolites in serum | 中国科学院大连化学物理研究所 | 2022-06-14 | — | — | CN | disclosed |
| US-10870633-B2 | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | Szegedi Tudományegyetem (HU) | 2020-12-22 | — | — | US | disclosed |
| US-10870633-B2 | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | Szegedi Tudományegyetem (HU) | 2020-12-22 | — | — | US | disclosed |
| EP-3423444-B1 | NOVEL TYPES OF C-3 SUBSTITUTED KINURENIC ACID DERIVATIVES WITH IMPROVED NEUROPROTECTIVE ACTIVITY | UNIV SZEGEDI (HU) | 2020-11-18 | — | — | EP | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326610-A2 | AZA-AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| WO-2002055079-A2 | AZA-AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | GRM2 4857/4885NCOA1 272/4885NCOA3 239/4885 |
| US-10870633-B2 | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | KYNU, KMO, PARK7 | GRM2 93/4885NCOA1 939/4885NCOA3 669/4885 |
| US-20090012118-A1 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | GRIN1, GRIN2A, GRIN2B | GRM2 23/4885NCOA1 292/4885NCOA3 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.